探究小剂量奥氮平联合米氮平对躯体形式障碍患者治疗的临床疗效与安全性

To Investigate the Clinical Efficacy and Safety of Low Dose Olanzapine Combined with Mirtazapine in the Treatment of Somatoform Disorders

目的:探讨小剂量奥氮平联合米氮平治疗躯体形式障碍的临床疗效与安全性。方法:选取我院2014年5月-2017年2月接受治疗的90例首发躯体形式障碍患者,以随机数表法将其分成观察组与对照组,各45例。观察组用小剂量奥氮平联合米氮平进行治疗,对照组仅用米氮平治疗,观察时间8周。用症状自评量表(SCL-90)对两组患者各时间点临床疗效进行测评(本次只针对焦虑、抑郁、躯体化3个症状评价因子),同时副反应量表(TESS)测评两组患者不同时间点的副反应出现情况。结果:治疗后,观察组患者治疗的总有效率明显高于对照组(P<0.01)。观察组患者治疗2周结束后、对照组治疗4周结束后各时间点症状评价因子评分明显低于治疗前(P<0.01或P<0.05);治疗4周结束后观察组各时间点症状评价因子评分明显低于对照组(P<0.01或P<0.05);两组副反应出现率对比差异无统计学意义(P>0.05)。结论:小剂量奥氮平联合米氮平对躯体形式障碍患者的临床疗效明显优于单用米氮平,能有效改善患者的焦虑、抑郁、躯体化等症状,安全性较高,应在临床进行推广。

Objective：To investigate the clinical efficacy and safety of low dose olanzapine combined with mirtazapine in the treatment of somatoform disorders.Methods：A total of 90 cases of patients with somatoform disorders treated in our hospital,to randomly divided into observation group and control group of 45 cases.The observation group was treated with low dose olanzapine combined with mirtazapine,while the control group was only treated with mirtazapine.The observation time was 8 weeks.Using the symptom checklist（SCL-90）was used to evaluate the clinical efficacy of two groups of patients at each time point（the only for anxiety,depression and somatization symptoms,3 evaluation factors）and side effects scale（TESS）on the time of the two groups of adverse events were evaluated.Results：After treatment,the total effective rate of the observation group was significantly higher than that of the control group（P〈0.01）.The observation group after 2 weeks of treatment,the control group after 4 weeks of treatment at each time point of symptom evaluation factor scores were significantly lower than before treatment（P〈0.01 or P〈0.05）;after 4 weeks of treatment,the observation group at each time point of assessment of symptoms factor score was significantly lower than the control group（P〈0.01 or P〈0.05）.There was no significantly difference in the incidence of side effects between the two groups（P〉0.05）.Conclusion：The dose of olanzapine combined with mirtazapine on the clinical curative effect of the treatment of patients with somatoform disorder is better than the single use of mirtazapine,anxiety,depression,somatization symptoms improved obviously,and higher safety,and is worthy of clinical promotion.